XFOR
NASDAQX4 Pharmaceuticals Inc.
Price$3.73+0.04 (+1.08%)
2026-03-052026-06-08
News · 26 weeks34-56%
2025-12-142026-06-07
Mix1890d
- SEC Filings9(50%)
- Other7(39%)
- Insider1(6%)
- Analyst1(6%)
Latest news
25 items- ANALYSTLeerink Partners initiated coverage on X4 Pharmaceuticals with a new price targetLeerink Partners initiated coverage of X4 Pharmaceuticals with a rating of Outperform and set a new price target of $12.00
- PRX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on May 29, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the "2019 Inducement Plan"). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 160,000 shares of X4's common stock. These stock awards were granted as an inducement material to the new employees entering into e
- PRX4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare ConferenceBOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 3:45 p.m. ET. A link to the live and archived webcast may be accessed on X4 Pharmaceuticals' website under the Investors section: Events and Presentations. About X4 Pharmaceuticals X4 Pharmaceuticals is a company focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet needs. Leveraging expertise in diseases of
- SECSEC Form EFFECT filed by X4 Pharmaceuticals Inc.EFFECT - X4 Pharmaceuticals, Inc (0001501697) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by X4 Pharmaceuticals Inc.SCHEDULE 13G/A - X4 Pharmaceuticals, Inc (0001501697) (Subject)
- SECAmendment: X4 Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K/A - X4 Pharmaceuticals, Inc (0001501697) (Filer)
- INSIDERChief Financial Officer Kirske David sold $72,820 worth of shares (16,961 units at $4.29), decreasing direct ownership by 9% to 176,293 units (SEC Form 4)4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
- SECSEC Form 144 filed by X4 Pharmaceuticals Inc.144 - X4 Pharmaceuticals, Inc (0001501697) (Subject)
- SECX4 Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - X4 Pharmaceuticals, Inc (0001501697) (Filer)
- SECSEC Form S-3 filed by X4 Pharmaceuticals Inc.S-3 - X4 Pharmaceuticals, Inc (0001501697) (Filer)
- PRX4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment by the end of Q3 2026 - - European Commission Approval of XOLREMDI® (Mavorixafor) Provides the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union - - Balance Sheet Provides Cash Runway through 2028 - BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today reported financial results for the first quarter ended March 31, 2026 and provided a corporate update. "Our top priority remains the execution and full enrollment of the pivotal 4WARD Phase 3 trial of mavorixaf
- SECSEC Form 10-Q filed by X4 Pharmaceuticals Inc.10-Q - X4 Pharmaceuticals, Inc (0001501697) (Filer)
- PRX4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union- European Commercialization will be Led by X4 Pharmaceuticals' Partner, Norgine - - Global, Pivotal Phase 3 Clinical Trial Ongoing to Evaluate Mavorixafor in Chronic Neutropenia - BOSTON, April 29, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, announced today that the European Commission (EC) has granted marketing authorization for XOLREMDI® (mavorixafor) capsules for the treatment of patients with WHIM syndrome in the European Union (EU). The approval follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). The marketing authori
- PRX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on March 31, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the "2019 Inducement Plan"). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 32,000 shares of X4's common stock. These stock awards were granted as an inducement material to the new employees entering into
- SECSEC Form DEFA14A filed by X4 Pharmaceuticals Inc.DEFA14A - X4 Pharmaceuticals, Inc (0001501697) (Filer)
- SECSEC Form DEF 14A filed by X4 Pharmaceuticals Inc.DEF 14A - X4 Pharmaceuticals, Inc (0001501697) (Filer)
- PRX4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment in Q3 2026 - - Positive Opinion from European Medicines Agency Recommending Marketing Authorization of Mavorixafor for the Treatment of WHIM Syndrome in the European Union - - Balance Sheet Provides Cash Runway through 2028 - BOSTON, March 17, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today reported financial results for the fourth quarter and year ended December 31, 2025 and provided a corporate update. "Our focus remains on our pivotal 4WARD trial in chronic neutropenia as we execute our strategy to deliver
- SECSEC Form 10-K filed by X4 Pharmaceuticals Inc.10-K - X4 Pharmaceuticals, Inc (0001501697) (Filer)
- ANALYSTGuggenheim initiated coverage on X4 Pharmaceuticals with a new price targetGuggenheim initiated coverage of X4 Pharmaceuticals with a rating of Buy and set a new price target of $12.00
- SECAmendment: SEC Form SCHEDULE 13G/A filed by X4 Pharmaceuticals Inc.SCHEDULE 13G/A - X4 Pharmaceuticals, Inc (0001501697) (Subject)
- PRX4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare ConferenceBOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that the management team will participate in a fireside chat at the Leerink Global Healthcare Conference on Wednesday, March 11, 2026 at 10:00 a.m. ET in Miami, FL. A link to the live and archived webcast may be accessed on X4 Pharmaceuticals' website under the Investors section: Events and Presentations. About X4 Pharmaceuticals X4 Pharmaceuticals is a company focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unme
- PRX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on February 27, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the "2019 Inducement Plan"). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 24,000 shares of X4's common stock. These stock awards were granted as an inducement material to the new employees entering i
- PRX4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome- Potential First and Only Therapy in the EU for Ultra-Rare Immune Disorder - BOSTON, Feb. 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of marketing authorization, under exceptional circumstances, of mavorixafor for the treatment of WHIM syndrome in the European Union (EU). The positive opinion will now be reviewed by the European Commission (EC) with a final approval decision anticipated in the second quarter of 2026. "This po
- SECAmendment: SEC Form SCHEDULE 13G/A filed by X4 Pharmaceuticals Inc.SCHEDULE 13G/A - X4 Pharmaceuticals, Inc (0001501697) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by X4 Pharmaceuticals Inc.SCHEDULE 13G/A - X4 Pharmaceuticals, Inc (0001501697) (Subject)
XFOR FAQ
7 questionsWhat does X4 Pharmaceuticals Inc. do?
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rear diseases. Its lead product candidate is mavorixafor, an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell...Where does XFOR stock trade?
X4 Pharmaceuticals Inc. (XFOR) is listed on NASDAQ.What sector and industry is XFOR in?
X4 Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did X4 Pharmaceuticals Inc. go public?
X4 Pharmaceuticals Inc. (XFOR) completed its IPO in 2017.What are analysts saying about XFOR?
X4 Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Leerink Partners: Outperform with a $1200.00 price target on 2026-06-02.What companies are similar to XFOR?
Notable peers in the same industry include RYTM (Rhythm Pharmaceuticals Inc.), BCRX (BioCryst Pharmaceuticals Inc.), DCPH (Deciphera Pharmaceuticals Inc.). Compare XFOR side-by-side with any of them on Quantisnow.How can I track XFOR on Quantisnow?
Quantisnow aggregates X4 Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow XFOR to receive live email and push alerts on every new disclosure.